These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 25134067

  • 21. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.
    Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ.
    Clin Chem; 2007 Oct; 53(10):1814-9. PubMed ID: 17702855
    [Abstract] [Full Text] [Related]

  • 22. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects.
    Kwakernaak AJ, Lambert G, Muller Kobold AC, Dullaart RP.
    Thyroid; 2013 Feb; 23(2):166-72. PubMed ID: 23106476
    [Abstract] [Full Text] [Related]

  • 23. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G, Petrides F, Chatelais M, Blom DJ, Choque B, Tabet F, Wong G, Rye KA, Hooper AJ, Burnett JR, Barter PJ, Marais AD.
    J Am Coll Cardiol; 2014 Jun 10; 63(22):2365-73. PubMed ID: 24632287
    [Abstract] [Full Text] [Related]

  • 24. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.
    Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ.
    J Lipid Res; 2008 Feb 10; 49(2):394-8. PubMed ID: 18033751
    [Abstract] [Full Text] [Related]

  • 25. Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients.
    Levenson AE, Haas ME, Miao J, Brown RJ, de Ferranti SD, Muniyappa R, Biddinger SB.
    Endocrinology; 2016 Apr 10; 157(4):1421-9. PubMed ID: 26824363
    [Abstract] [Full Text] [Related]

  • 26. Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation.
    Tran-Dinh A, Levoye A, Lambert G, Louedec L, Journé C, Meilhac O, Amarenco P.
    Stroke; 2014 Oct 10; 45(10):3086-8. PubMed ID: 25123222
    [Abstract] [Full Text] [Related]

  • 27. The effects of estrogen on serum level and hepatocyte expression of PCSK9.
    Guo W, Fu J, Chen X, Gao B, Fu Z, Fan H, Cui Q, Zhu X, Zhao Y, Yang T, Fan D, Zhou H.
    Metabolism; 2015 Apr 10; 64(4):554-60. PubMed ID: 25665485
    [Abstract] [Full Text] [Related]

  • 28. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
    Vergès B, Duvillard L, Brindisi MC, Gautier E, Krempf M, Costet P, Cariou B.
    Atherosclerosis; 2011 Nov 10; 219(1):342-8. PubMed ID: 21889145
    [Abstract] [Full Text] [Related]

  • 29. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects.
    Kappelle PJ, Lambert G, Dahlbäck B, Nielsen LB, Dullaart RP.
    Atherosclerosis; 2011 Feb 10; 214(2):492-4. PubMed ID: 21122852
    [Abstract] [Full Text] [Related]

  • 30. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
    Kwakernaak AJ, Lambert G, Slagman MC, Waanders F, Laverman GD, Petrides F, Dikkeschei BD, Navis G, Dullaart RP.
    Atherosclerosis; 2013 Feb 10; 226(2):459-65. PubMed ID: 23261172
    [Abstract] [Full Text] [Related]

  • 31. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
    Nozue T, Hattori H, Ishihara M, Iwasaki T, Hirano T, Kawashiri MA, Yamagishi M, Michishita I.
    Am J Cardiol; 2013 May 15; 111(10):1415-9. PubMed ID: 23433768
    [Abstract] [Full Text] [Related]

  • 32. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease.
    Zhang Y, Zhu CG, Xu RX, Li S, Guo YL, Sun J, Li JJ.
    J Clin Lipidol; 2014 May 15; 8(5):494-500. PubMed ID: 25234562
    [Abstract] [Full Text] [Related]

  • 33. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M, Terao Y, Ayaori M, Uto-Kondo H, Iizuka M, Yogo M, Hagisawa K, Takiguchi S, Yakushiji E, Nakaya K, Ogura M, Komatsu T, Ikewaki K.
    Arterioscler Thromb Vasc Biol; 2014 Jun 15; 34(6):1171-8. PubMed ID: 24675665
    [Abstract] [Full Text] [Related]

  • 34. Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer.
    Ozkan C, Akturk M, Altinova AE, Cerit ET, Gulbahar O, Yalcin MM, Cakir N, Balos Toruner F.
    Endocr J; 2015 Jun 15; 62(12):1091-9. PubMed ID: 26490048
    [Abstract] [Full Text] [Related]

  • 35. PCSK9 and lipid lowering drugs.
    Guo YL, Zhang W, Li JJ.
    Clin Chim Acta; 2014 Nov 01; 437():66-71. PubMed ID: 25036764
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D, Pöss J, Böhm M, Laufs U.
    J Am Coll Cardiol; 2013 Oct 15; 62(16):1401-8. PubMed ID: 23973703
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.